Literature DB >> 2979039

Campylobacter pylori-associated gastritis: attempts to eradicate the bacteria by various antibiotics and anti-ulcer regimens.

Y Glupczynski, A Burette, J F Nyst, C De Prez, E De Koster, M Deltenre.   

Abstract

The efficacy of various antimicrobial and anti-ulcer agents on the eradication of Campylobacter pylori in patients with antral gastritis or duodenal ulcers was investigated by several open studies or double-blind, placebo-controlled protocols. Among the anti-ulcer agents, ranitidine, cimetidine or sucraflate had no effect on C. pylori. Colloidal bismuth subcitrate achieved clearance of C. pylori in 40% of treated patients at the end of therapy but a high relapse rate (14/16 patients) was observed after a 6-month follow-up period. The antibacterial agents doxycycline, minocycline, ofloxacin, clindamycin, paromomycin and nifuroxazide failed to eradicate C. pylori in most patients. By contrast, short term elimination of C. pylori could be achieved in more than 90% of patients treated with amoxycillin. However, relapse occurred as a rule in all amoxycillin-treated patients within one month after therapy. Overall, we observed no correlation between the in-vitro activity of the different antibacterial agents and their in vivo efficacy. Development of resistance during therapy does not seem to account for this discrepancy since it occurred only with ofloxacin. On the basis of these results, we conclude that long term eradication of C. pylori from the gastric antrum cannot be achieved after monotherapy either with antibiotics or with bismuth salts.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2979039

Source DB:  PubMed          Journal:  Acta Gastroenterol Belg        ISSN: 1784-3227            Impact factor:   1.316


  5 in total

1.  Evaluation of a commercially available complement fixation test for diagnosis of Helicobacter pylori infection and for follow-up after antimicrobial therapy.

Authors:  H Goossens; Y Glupczynski; A Burette; C Van den Borre; C DePrez; J Bodenmann; A Keller; J P Butzler
Journal:  J Clin Microbiol       Date:  1992-12       Impact factor: 5.948

2.  Susceptibility of Helicobacter pylori to metronidazole.

Authors:  M López-Brea; E Martín; C López-Lavid; J C Sanz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-12       Impact factor: 3.267

Review 3.  Helicobacter pylori: the place of the new macrolides in the eradication of the bacteria in peptic ulcer disease.

Authors:  A Burette; Y Glupczynski
Journal:  Infection       Date:  1995       Impact factor: 3.553

4.  In vitro antimicrobial susceptibility testing of Helicobacter felis, H. bizzozeronii, and H. salomonis.

Authors:  K Van den Bulck; A Decostere; I Gruntar; M Baele; B Krt; R Ducatelle; F Haesebrouck
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

5.  Evaluation of a commercially available second-generation immunoglobulin G enzyme immunoassay for detection of Helicobacter pylori infection.

Authors:  H Goossens; Y Glupczynski; A Burette; C Van den Borre; J P Butzler
Journal:  J Clin Microbiol       Date:  1992-01       Impact factor: 5.948

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.